ストックスクリーナーアプリを入手
2.99
1.97%
-0.06
アフターアワーズ：
2.99
前日終値:
$3.05
開ける：
$3.0951
24時間の取引高:
31,483
Relative Volume:
0.07
時価総額：
$9.10M
収益：
-
当期純損益:
$2.81M
株価収益率:
-0.2084
EPS:
-14.3497
ネットキャッシュフロー:
$7.14M
1週間 パフォーマンス:
-5.97%
1か月 パフォーマンス:
-1.32%
6か月 パフォーマンス:
-21.93%
1年 パフォーマンス:
-36.25%
1日の値動き範囲:
$2.99
$3.10
1週間の範囲:
$2.96
$3.2328
52週間の値動き範囲:
$2.51
$4.80
Kiora Pharmaceuticals Inc Stock (KPRX) Company Profile
名前
Kiora Pharmaceuticals Inc
セクター
電話
781-788-8869
住所
332 ENCINITAS BOULEVARD, ENCINITAS
KPRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KPRX
Kiora Pharmaceuticals Inc
|
2.99 | 9.28M | 0 | 2.81M | 7.14M | -14.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Kiora Pharmaceuticals Inc (KPRX) 最新ニュース
What drives Kiora Pharmaceuticals Inc. stock priceDynamic investment opportunities - Autocar Professional
What analysts say about Kiora Pharmaceuticals Inc. stockPhenomenal trading returns - PrintWeekIndia
Kiora Pharmaceuticals Secures US Patent for KIO-104 - Ophthalmology Times
Kiora Pharmaceuticals Inc. Stock Analysis and ForecastExtraordinary market timing - Autocar Professional
Is Kiora Pharmaceuticals Inc. a good long term investmentPowerful profit generation - jammulinksnews.com
KPRX Receives Positive Outlook Following New U.S. Patent | KPRX Stock News - GuruFocus
Kiora Pharmaceuticals stock rises after receiving patent for KIO-104 - Investing.com India
Kiora Pharmaceuticals stock rises after receiving patent for KIO-104 By Investing.com - Investing.com Nigeria
Kiora Pharmaceuticals receives patent for ocular disease treatment By Investing.com - Investing.com South Africa
Kiora Pharmaceuticals receives patent for ocular disease treatment - Investing.com Australia
Kiora Secures Crucial Patent for Eye Disease Drug KIO-104 as Phase 2 Trial Advances - Stock Titan
Why Kiora Pharmaceuticals Inc. stock attracts strong analyst attentionFree Top-Rated Stock Analysis - Newser
Kiora Pharmaceuticals (KPRX) Upgraded to Strong Buy: Here's What You Should Know - MSN
Retinitis Pigmentosa Treatment Market Driven by Gene Therapy - openPR.com
How Kiora Pharmaceuticals Inc. stock performs during market volatilityFree Smart Money Stock Analysis - Newser
What makes Kiora Pharmaceuticals Inc. stock price move sharplyPredictable Return Stock Picks - Newser
Kiora Pharmaceuticals (NASDAQ:KPRX) Trading 1.8% Higher – Here’s Why - Defense World
Kiora Pharmaceuticals (NASDAQ:KPRX) Trading Down 0.3% – Here’s Why - Defense World
Kiora Pharmaceuticals and Senju Pharmaceutical partner on KIO-301 for retinal disease treatment in Asia - Ophthalmology Times
kiora pharmaceuticals reports results of annual shareholder meeting By Investing.com - Investing.com South Africa
kiora pharmaceuticals reports results of annual shareholder meeting - Investing.com
Kiora Pharmaceuticals Holds Annual Meeting, Elects Directors - TipRanks
Oil Prices Climb While US Equity Futures Stutter - Finimize
MAG 8 Momentum: NIVF, TRAW, KPRX, PNPN.V Lead $3 Undercard SurgeMore Stocks Inside! - openPR.com
Pre-market Movers: STSS, SGMT, NIVF, OGEN... - RTTNews
MAG 8 Momentum: NIVF, TRAW, KPRX, PNPN.V Lead $3 Undercard Surge – More Stocks Inside! - FinancialContent
Markets | American Financial Group, Inc. - FinancialContent
Kiora Pharmaceuticals inks potential $110 million deal with Senju By Investing.com - Investing.com South Africa
Kiora Pharmaceuticals Inc (KPRX) 財務データ
収益
当期純利益
現金流量
EPS
0.97%
0.22%
大文字化:
|
ボリューム (24 時間):